Home > Resources > Whitepapers > Future Trends In Pharmaceutical and Biotech Distribution

Future Trends In Pharmaceutical and Biotech Distribution

Today’s Pharma and Bio-Tech supply chain is more complex than ever! Multiple events occurring on a daily basis are shaping the competitive and regulatory environment in which channel members operate their business. ASP regulation is changing, and non-conventional players (such as 3PLs) are threatening to dis-intermediate conventional players.

Spotlight

ProBioGen AG

ProBioGen is an internationally operating, privately held Contract Development & Manufacturing Organization (CDMO), focusing on Cell Line Engineering, Process Development and GMP Manufacturing of Biopharmaceuticals (Therapeutic Proteins and Viral Vaccines).

OTHER WHITEPAPERS

Document quality control emerges as a discipline in its own right

whitePaper | November 19, 2022

Compiling a quality regulatory submission is a basic requirement for biopharmaceutical companies. Poor quality documents could lead to rejection of a regulatory application,

Impurity profiling and analysis of TheraPure GMP nucleotides

whitePaper | March 22, 2023

Nucleoside triphosphates (NTPs) are key building blocks of many nucleic acid therapeutics and vaccines. These molecules are a vital component of revolutionary new medicines.

Early engagement and regulatory considerations for biotech

whitePaper | March 24, 2023

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines and first-inclass immunotherapies.

How advanced purification technologies are speeding the hunt for new protections against disease

whitePaper | November 24, 2022

Smallpox was the first infectious disease for which an effective vaccine was developed. In the late 1700s, British doctor Edward Jenner devised a method to inoculate people with cowpox pus to give them immunity against smallpox, a much more deadly disease.

Accelerating Global Access to Gene Therapies: Case Studies from Lowand Middle-Income Countries

whitePaper | October 18, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result

Growing a circular economy with fungal biotechnology

whitePaper | August 17, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans.